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A B S T R A C TDespite the use of identical clinical trial data (Anastrazole, Tamoxifen,
Alone or in Combination for the adjuvant treatment of postmenopausal
women with localised hormone receptor-positive breast cancer data), not
dependent on differences between countries, the outcome of 11 pub-
lished cost-effectiveness analyses varied more than 20-fold. The observed
wide variation in predicted life-years gained (a parameter derived from
clinical trial data) demonstrates that authors used substantially differentsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.06.012
s@nki.nl.
ondence to: Jan H.M. Schellens, Departments of C
smanlaan 121, 1066 CX Amsterdam, The Netherlmethods for handling the same data. We therefore consider it to be of
utmost importance to strive for standardization of and better guidance
for disease-speciﬁc modeling in economic evaluations.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Worldwide, health care costs are dramatically increasing and
difﬁcult to control. Of the various factors affecting the increase,
that is, technological advances, aging of the population, and drug
costs, drug expenditure appears to be the most tangible and is
therefore a logical target for cost containment. To ensure that
health care professionals deliver care of the best possible quality
and of the best value for money, a large number of health policy
decision bodies over the world have incorporated cost-
effectiveness evaluations in their drug reimbursement decision
process, after witnessing a positive beneﬁt-risk and added ther-
apeutic value. In these evaluations, long-term effectiveness is
predicted by mathematical modeling using available short-term
clinical efﬁcacy data [1], for example, of the Herceptin Adjuvant,
Finland Herceptin (Trastuzumab), and Anastrazole, Tamoxifen,
Alone or in Combination for the adjuvant treatment of postme-
nopausal women with localised hormone receptor-positive
breast cancer (ATAC) trials. Because the outcome of cost-
effectiveness studies can affect the availability of life-saving
drugs to patients, it is essential that the methods for these
evaluations are valid and the results robust. It is alarming,
however, that this is often not guaranteed, as demonstrated by
the case of the ATAC trial.
Results of the ATAC trial revealed a signiﬁcant improvement
in disease-free survival of patients treated with anastrazole than
with tamoxifen [2]. Data from this large trial have since formed
the basis for a considerable number of cost-effectiveness evalua-
tions in various jurisdictions.Trial efﬁcacy data are used to populate mathematical models
that aim to determine value for money. Value for money, as main
outcome of cost-effectiveness evaluations, is expressed as the
incremental cost-effectiveness ratio (ICER). The ICER is the ratio
of the difference in total costs of two interventions (incremental
costs) and the difference in effects, where effects are commonly
expressed as life-year (LY) gained or quality-adjusted life-year
(QALY) gained. ICERs are often used to determine whether a new
intervention is considered cost-effective by comparing the ICER
with a cost-effectiveness threshold that has been deﬁned within
a jurisdiction. A well-known threshold is the one implemented in
the United Kingdom by the National Institute for Health and
Clinical Excellence. Their formal threshold has been set over a
range of £20,000 to £30,000 ($31,000–$47,000) per QALY gained,
meaning that therapies having ICERs within this range are
considered cost-effective and therapies having ICERs above this
threshold are not considered cost-effective, and therefore are
often not reimbursed by the National Health Service.
After the ATAC trial publication in 2002, 11 cost-effectiveness
evaluations were published by using clinical efﬁcacy outcomes of
the trial as primary input to the cost-effectiveness models. Analyses
were performed in Belgium, the United Kingdom, Brazil, Germany,
the United States, Canada, and Spain. Using the same comparator
and the same efﬁcacy data, the 11 economic evaluations reported a
wide variation in ICERs for anastrazole, ranging from $4,868 per LY
gained in Belgium to $92,657 per LY gained in Spain, and from
$4,546 per QALY gained to $147,926 per QALY gained in Belgium andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
linical Pharmacology and Molecular Pathology, The Netherlands
ands.
Table 1 – Overview of outcomes of economic evaluations making use of ATAC clinical trial data, in order of
increasing cost-effectiveness.
Author, journal, year of
publication
Country Life-
years
gained
QALYs
gained
Incremental
costs ($)
Cost per
LY gained
($)
Cost per
QALY
gained ($)
Industry
sponsored
Moeremans et al., Int J
Gynecol Cancer,
2006;16:576–8
Belgium 0.353 0.378 1,718 4,868 4,546 No
Karnon et al., Eur J Health
Econ, 2008;9:171–83*
UK 0.350 0.360 3,793 10,836 10,536 Yes
Fonseca et al., Rev Assoc
Med Bras, 2009;55:410–5
Brazil 0.550 NA 12,213 22,042 NA Yes
Karnon et al., Eur J Health
Econ, 2008;9:171–83†
UK 0.250 0.260 4,348 17,374 16,965 Yes
Locker et al., Breast Cancer
Res Treat, 2007;106:229–38
US 0.221 0.257 5,173 17,392 20,096 Yes
Rocchi and Verma, Support
Care Cancer, 2006;14:917–
27‡
Canada 0.194 0.218 4,536 23,404 20,805 Yes
Skedgel et al., Breast,
2007;16:252–61
Belgium NA 0.231 5,306 NA 22,967 Yes
Skedgel et al., Breast Cancer
Res Treat, 2007;101:325–
33§
Canada NA 0.227 5,055 NA 22,259 No
Rocchi and Verma, Support
Care Cancer, 2006;14:917–
27||
Canada 0.192 0.208 4,670 24,286 22,465 Yes
Lux et al., Onkologie,
2010;33:155–66
Germany 0.290 0.320 7,753 26,730 23,952 Yes
Mansel et al., Br J Cancer,
2007;97:152–61
UK 0.230 0.244 6,605 28,626 27,024 Yes
Skedgel et al., Breast Cancer
Res Treat, 2007;101:325–
33¶
Canada NA 0.092 4,970 NA 54,006 No
Hillner et al., Am Cancer
Soc, 2004;101:1311–22
US 0.160 0.123 6,649 40,298 75,338 No
Gil et al., Clin Transl Oncol,
2006;8:339–48#
Spain 0.535 0.285 25,261 47,216 88,634 Yes
Gil et al., Clin Transl Oncol,
2006;8:339–48**
Spain 0.182 0.114 16,863 92,657 147,926 Yes
Notes. Karnon et al., Rocchi and Verma, Skedgel et al., and Gil et al. presented each two base-case analyses with different modeling methods in
their study.
Therefore, each separate analysis was included in this table.
NA, not analyzed; QALY, quality-adjusted life-year.
 Carryover effect of 5 y.
† No carryover effect.
‡ 3-y interim analysis.
§ 20-y time horizon.
|| 5-y interim analysis.
¶ 10-y time horizon.
# 20-y time horizon.
 10-y time horizon.
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ICERs between countries was the variation in reported QALYs (from
0.092 to 0.378) and, more remarkably, the substantial variation in LY
gained, from 0.16 to 0.550 [3] [Table 1].
It is well known that cost-effectiveness evaluations performed in
different countries are subject to variation caused by country-speciﬁc
populations, health care system characteristics, and country-
speciﬁc values for prizes and health-related quality of life, so-
called transferability factors [4]. In a recent review, a clear over-
view was given of the long list of factors affecting the trans-
ferability of cost-effectiveness evaluations between countries [5].
In our case, the differences found in the incremental costs of boththerapies between countries could be ascribed to several of these
transferability factors. For instance, differences in drug costs of
anastrazole and tamoxifen, the costing factor with the highest
impact on incremental costs, varied from $2.88 in Belgium to
$5.94 per patient per day in Spain, thereby resulting in minimally
a twofold difference in incremental costs. Furthermore, the
differences in QALY estimates could be caused by differences in
patient preferences for speciﬁc health-related outcomes (utilities)
between countries. The strength for these preferences is meas-
ured on a scale, with zero reﬂecting death and one reﬂecting
perfect health. For example, local recurrence, an essential health-
related outcome, was valued with a utility of 0.911 in the United
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 0 0 – 1 1 0 21102Kingdom and 0.816 in Canada. Consequently, the ICERs reﬂecting
costs per QALY can vary between countries (Table 1).
In contrast, the estimated differences in LY gained, which are
derived from the same efﬁcacy data of the ATAC trial, are less
simply explained by transferability characteristics, especially
in situations in which cost-effectiveness evaluations are per-
formed in the same country and differences in transferability
factors cannot play a role. Therefore, other explanations for
differences between these evaluations must be present.
In a recent analysis, we demonstrated that differences in
modeling methods related to extrapolation of the original ATAC
data over time are the main cause of variability in outcome [3].
Investigator’s own choices of time horizon, hazard rate for
recurrence, incidence of recurrence, and inclusion of a carryover
effect (i.e., an effect of treatment that persists after treatment
was stopped) were the main causes for the wide variation in cost-
effectiveness outcomes. Time horizon, the time period over
which costs and effects are taken into account, varied between
studies from 10 years to lifetime in the studies discussed here. In
hormone receptor–positive breast cancer, relapse after 10 years
can develop in a relevant subset of patients, clearly indicating
that a time horizon of 10 years is too short. Choice of hazard rate
for recurrence varied between the use of the disease-free (pri-
mary ATAC trial end point) and recurrence-free (secondary end
point) hazard ratio. Important differences in the rate of recur-
rence were also applied, varying from constant and time-
dependent rates to even Weibull functions. Finally, although a
carryover effect of approximately 5 years for anastrazole was
conﬁrmed in several clinical trials, some authors included no
carryover effect, a carryover effect lasting for 5 years, or even a
lifetime carryover effect for anastrazole compared with tamox-
ifen. Sensitivity analyses in a Canadian study demonstrated that
inclusion of the carryover effect lasting for 5 years lead to a 46%
reduction in cost per LY gained (i.e., $38,588–$20,805), demon-
strating the necessity of including a carryover effect, if well
established.
Although currently economic evaluations are extensively
used to guide decision making about drug reimbursement and
therefore drug availability to the community, our observations
demonstrate that important challenges still exist in this area.
Reported differences in ICERs and LY gained of the individual
cost-effectiveness evaluations are largely determined by the
modeling methods used by individual investigators, rather than
by hard clinical efﬁcacy data or well-deﬁned and transparent
transferability factors. Robustness and validity of the cost-effectiveness estimates, therefore, can seriously come into ques-
tion, potentially undermining the added value of such evidence
in the decision-making process, which thereby also highlights
the need for adequate training for policymakers to ensure correct
interpretation of ﬁndings from cost-effectiveness studies. At last,
although industry-induced bias is relevant in the development of
cost-effectiveness analyses, we are not able to make ﬁrm state-
ments regarding the inﬂuence within these analyses because
only three analyses were not sponsored by industry and studies
sponsored by and not sponsored by industry both calculated high
as well as low ICERs.
The widely divergent outcomes of the 11 cost-effectiveness
evaluations based on one and the same ATAC trial demonstrates
the need for standardization and better guidance for disease-
speciﬁc modeling in economic evaluations in addition to general
health economic guidance provided by current guidelines. This
disease-speciﬁc guidance is ideally provided through collabora-
tion of international stakeholders, that is, health economists,
policymakers, and physicians. Wide acceptance and implemen-
tation of crystal clear guidance should improve the standardiza-
tion of the methods and the robustness of the results of future
cost-effectiveness evaluations and decrease possible inﬂuence of
study sponsorship on outcomes.
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